GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Deferred Policy Acquisition Costs

Merus NV (STU:2GH) Deferred Policy Acquisition Costs


View and export this data going back to 2021. Start your Free Trial

What is Merus NV Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Merus NV (STU:2GH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Deferred Policy Acquisition Costs
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.